Militia Capital Partners LP Invests $3.67 Million in Align Technology, Inc. $ALGN

Key Points

• Militia Capital Partners LP acquired 23,100 shares of Align Technology, valued at approximately $3.67 million, making it the firm's 9th biggest holding.
• Align Technology reported Q2 earnings of $2.49 per share, missing estimates by $0.08, with a revenue of $1.01 billion versus expected $1.06 billion.
• The company authorized a $200 million stock buyback, indicating its belief that shares are undervalued.

Militia Capital Partners LP acquired a new stake in Align Technology, Inc. (NASDAQ:ALGN - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 23,100 shares of the medical equipment provider's stock, valued at approximately $3,670,000. Align Technology makes up about 2.9% of Militia Capital Partners LP's portfolio, making the stock its 9th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Orion Capital Management LLC bought a new stake in Align Technology in the 4th quarter valued at $42,000. Compagnie Lombard Odier SCmA acquired a new stake in Align Technology in the 1st quarter valued at $32,000. Center for Financial Planning Inc. acquired a new stake in Align Technology in the 1st quarter valued at $35,000. SVB Wealth LLC acquired a new stake in Align Technology in the 1st quarter valued at $36,000. Finally, Mather Group LLC. increased its stake in Align Technology by 375.0% in the 1st quarter. Mather Group LLC. now owns 437 shares of the medical equipment provider's stock valued at $69,000 after buying an additional 345 shares during the last quarter. 88.43% of the stock is owned by institutional investors.

Align Technology Price Performance

ALGN stock traded up $0.38 during trading on Wednesday, reaching $132.20. 237,642 shares of the company were exchanged, compared to its average volume of 1,221,788. Align Technology, Inc. has a twelve month low of $127.70 and a twelve month high of $262.87. The company has a 50-day moving average of $158.09 and a two-hundred day moving average of $169.27. The company has a market capitalization of $9.58 billion, a price-to-earnings ratio of 22.30, a P/E/G ratio of 1.48 and a beta of 1.65.

Align Technology (NASDAQ:ALGN - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.08). Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the company posted $2.41 earnings per share. The company's revenue was down 1.6% compared to the same quarter last year. Align Technology has set its Q3 2025 guidance at EPS. On average, analysts forecast that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology declared that its Board of Directors has approved a stock repurchase plan on Tuesday, August 5th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ALGN shares. Zacks Research lowered shares of Align Technology from a "hold" rating to a "strong sell" rating in a research note on Monday, September 1st. Wells Fargo & Company lowered their price objective on shares of Align Technology from $246.00 to $199.00 and set an "overweight" rating on the stock in a research note on Thursday, July 31st. Morgan Stanley restated an "equal weight" rating and set a $154.00 price objective (down from $249.00) on shares of Align Technology in a research note on Thursday, July 31st. Stifel Nicolaus lowered their price objective on shares of Align Technology from $275.00 to $200.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Finally, Evercore ISI boosted their price objective on shares of Align Technology from $200.00 to $220.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $215.00.

Insider Buying and Selling

In related news, CEO Joseph M. Hogan purchased 7,576 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was bought at an average price of $131.49 per share, for a total transaction of $996,168.24. Following the purchase, the chief executive officer directly owned 184,945 shares in the company, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.66% of the company's stock.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.